Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dezima In-Licenses CETP Inhibitor Program from MTPC

Published: Thursday, April 25, 2013
Last Updated: Thursday, April 25, 2013
Bookmark and Share
World-renowned dyslipidemia experts join Dezima’s Scientific Advisory Board.

Dezima Pharma (‘Dezima’) has announced the in-licensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed.

DEZ-001 has completed single and multiple ascending dose studies showing an unprecedented effect on high density lipoprotein (HDL) and low density lipoprotein (LDL) levels in healthy volunteers with a very favourable side-effect profile.

The company plans to support clinical development of DEZ-001 to Phase 3 clinical trials.

Professor John Kastelein, founder of Dezima, co-founder of UniQure and advisor to Forbion Capital Partners, identified DEZ-001 as a potentially best-in-class, potent and safe CETP inhibitor.

At the same time, Dezima also reported the strengthening of its Scientific Advisory Board (SAB) with the addition of two world-leading experts in the dyslipidemia space: Dr Philip Barter, President of the International Atherosclerosis Society and Conjoint Professor at The University of New South Wales, Sydney, Australia, and Dr Bryan Brewer, Director at Washington Cardiovascular Associates and Senior Research Consultant of Lipoprotein and Atherosclerosis Research at the Medstar Research Institute, Washington DC, USA.

Professor Kastelein, Dezima’s CSO and Chairman of its SAB, commented: “CETP inhibitors hold enormous potential to further normalize lipid levels in millions of dyslipidemic patients worldwide. This product was a compelling in-licensing prospect because of its promising early clinical efficacy and safety profile. By applying a smart development program, DEZ-001 could potentially enter the market at a time similar to competing CETP inhibitors.”

Sander van Deventer, Dezima’s interim-CEO and General Partner at Forbion Capital Partners, who seed-financed Dezima together with BioGeneration Ventures, added: “The dyslipidemia space represents an attractive investment opportunity due to the continued high unmet medical need and the introduction of several next-generation therapeutic approaches. The addition of these two renowned experts to Dezima’s SAB will support the company in advancing DEZ-001, and in helping to identify additional earlier-stage dyslipidemia assets in order to develop a range of promising therapies in the CVD field.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dezima Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001
TULIP study will investigate the effects of different doses of DEZ-001 on CVD biomarkers.
Friday, August 30, 2013
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Rice Disease-Resistance Discovery Closes the Loop for Scientific Integrity
Researchers reveal how disease resistant rice detects and responds to bacterial infections.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!